GHK-Cu — Research Overview

Research Overview

GHK-Cu research examines a copper-binding tripeptide and its relationship to extracellular-matrix synthesis and tissue-remodeling processes. Much of the foundational evidence is from laboratory systems. [1][2]

What the Compound Is

The copper complex of glycyl-L-histidyl-L-lysine. The peptide and its copper complex must be identified accurately, and study findings depend on formulation and experimental conditions. [1][2]

Regulatory or Investigational Status

The AUVYRON presentation is a research material. Cosmetic use and laboratory publications do not establish FDA approval as a therapeutic injectable. FDA highlights characterization and immunogenicity concerns for injectable compounded GHK-Cu. [3]

Mechanisms or Pathways Under Investigation

Fibroblast experiments have examined collagen and sulfated glycosaminoglycan synthesis. These are components of the extracellular matrix. Their response in cell culture does not establish visible rejuvenation or tissue repair in people. [1][2]

Major Research Context

Foundational work used cultured fibroblasts to study matrix-related responses. Topical, cellular and animal research involves different exposures and cannot be treated as evidence for an interchangeable systemic formulation. [1][2][3]

Published Research Highlights

In vitro · Collagen synthesis

Maquart and colleagues reported stimulation of collagen synthesis in fibroblast cultures exposed to GHK-Cu. The endpoint was a laboratory measure. [1]

In vitro · Matrix components

Wegrowski and colleagues studied glycosaminoglycan synthesis in human fibroblast cultures and described a concentration-dependent response. [2]

Evidence Level and Research Limitations

Cultured human cells are not a clinical trial in humans. These sources do not establish an injectable regimen, hair-restoration outcome or anti-aging benefit. Translating matrix biomarkers to clinical results requires controlled human evidence and product-specific safety data. [1][2][3]

Selected Scientific References

Maquart et al. Collagen synthesis in fibroblast cultures with GHK-Cu. FEBS Letters, 1988. ↗In vitro study
Wegrowski et al. Sulfated glycosaminoglycan synthesis with GHK-Cu. FEBS Letters, 1992. ↗In vitro study
FDA. Selected peptide safety considerations, including injectable GHK-Cu. ↗Official regulatory material

Educational and Research Disclaimer

This page is for educational and scientific-reference purposes. It does not provide medical advice, diagnosis, treatment recommendations, dosing guidance or instructions for human use. References concern the specific materials and conditions studied; they are not evidence that an AUVYRON product has been evaluated in those studies. Product presentations are catalog identifiers, not use instructions.

FOR RESEARCH USE ONLY. NOT FOR HUMAN OR VETERINARY USE.